<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427503</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PEN-2015-11</org_study_id>
    <nct_id>NCT02427503</nct_id>
  </id_info>
  <brief_title>ATP Project (Asthma afTer Polypectomy)</brief_title>
  <acronym>ATP</acronym>
  <official_title>Sinonasal Functional Impact of Endoscopic Surgery for Bilateral Polyposis on Bronchial Inflammation, Control and Lung Function in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitat Autonoma de Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation of the nasal and bronchial mucosa characterizing rhinitis and asthma are
      probably manifestations of the same disease. Multiple functional observations, pathogenic and
      clinical support that assertion. It is noteworthy that most asthma patients, who underwent a
      nasal endoscopic polypectomy, improve your asthma after surgery. This improvement would be
      related to the administration of oral steroids that these patients usually receive after
      surgery, or the disappearance of nasal discomfort caused by nasal polyps to improve
      ventilation. But this does not explain why this improvement, in some cases lasting for months
      after the operation, and without receiving oral steroids. It is speculated that severe nasal
      inflammation due to nasal polyps stimulate the bone marrow to produce more eosinophils, an
      increased supply of blood eosinophils, and consequently, a major bronchial eosinophilic
      inflammation, aggravating asthma. However, it is noteworthy that studies have evaluated the
      clinical impact in asthma after endoscopic nasal polypectomy, are scarce or performed on a
      small number of cases, the results are inconsistent and do not allow categorically whether or
      not such positive association. And more importantly, none of them included measurements of
      airway inflammation and hypothesized relationship between bronchial eosinophilic inflammation
      and nasal polyposis, aclarar.La remains finding that provides nasal endoscopic polypectomy
      objective improvement of severe asthma it could be a future therapeutic option to consider in
      patients with asthma and rhinosinusal polyposis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sinonasal polyposis (SP) is a chronic inflammatory disease of the lining of the nasal
      passages and sinuses, with a prevalence of approximately 2-3% of the general population. The
      prevalence of asthma in patients diagnosed with SP is much greater than that of the general
      population and can reach half of the cases and indicate a more severe phenotype and worse
      control in asthmatic patients without SP. It is possible that the pathophysiologic mechanisms
      underlying the development of SP and concomitant asthma are the same and both processes can
      be considered the same disease.

      Recommendations of major clinical practice guidelines for the treatment of SP include
      administration of intranasal topical steroids at high doses, and in subjects who do not
      respond to this treatment or are more severe, administering a course of systemic steroids
      orally for 10-14 days or surgical intervention including polypectomy and removal of the
      diseased mucosa endoscopically, known as functional endoscopic sinus surgery (FESS).

      In this context, it is noteworthy that most asthma patients, who underwent functional
      endoscopic sinus surgery for bilateral polyposis (FESS-BP) stated it dramatically improved
      their asthma after surgery. This improvement could be related to the effect of oral steroids
      these patients often receive after surgery, or the disappearance of nasal discomfort caused
      by nasal polyps as ventilation improves after the intervention. However, these reasons do not
      sufficiently explain the fact that this improvement, in some cases extends for months after
      surgery, when patients are no longer receiving oral steroids.

      It has been speculated that severe nasal inflammation which involves the presence of nasal
      polyps would constantly stimulate the bone marrow, causing on the one hand increased
      production of eosinophils and the other an increase in adhesiveness, and thus, an important
      eosinophilic bronchial inflammation. This is in line with a usual clinical observation
      according to which patients with asthma and sinonasal polyposis, often suffer more severe
      asthma; and severe sinus inflammation is one of the aggravating factors recognized in severe
      uncontrolled asthma.

      However, studies that have assessed the clinical impact in asthma after FESS-BP, are only a
      few or have been performed on a small number of cases. Consequently, the results are
      inconsistent and do not allow to categorically establish whether this positive association
      exists or not. Most importantly, however, none of them included measurements of bronchial
      inflammation in the study variables, so that the hypothesis of the possible relationship
      between eosinophilic bronchial inflammation and nasal polyposis remains without having been
      tested.

      Moreover, the finding that the FESS-BP provides an objective improvement of asthma, could be
      a future therapeutic option to consider in patients with severe asthma and sinonasal
      polyposis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Breath inflammation measured by the fractional exhaled nitric oxide (FeNO)</measure>
    <time_frame>12 months</time_frame>
    <description>part per billion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma control bases on the ACT Questionnaire (Asthma Control Test)</measure>
    <time_frame>12 month</time_frame>
    <description>5-25 points, on 5 is bad control and 25 is the maximun asthma control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry measure FEV1</measure>
    <time_frame>12 month</time_frame>
    <description>percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum and blood test</measure>
    <time_frame>12 month</time_frame>
    <description>eosinophils percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal, inhalated or oral steroid treatment</measure>
    <time_frame>12 months</time_frame>
    <description>micrograms/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini questionnaire of quality of life (MiniAQLQ)</measure>
    <time_frame>12 months</time_frame>
    <description>1-7 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of chonic rhinosinusitis (SNOT 22)</measure>
    <time_frame>12 month</time_frame>
    <description>0-5 points</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Asthma</condition>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Asthma with NP and require surgery</arm_group_label>
    <description>Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma with NP and NOT require surgery</arm_group_label>
    <description>Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Asthma with NP and require surgery</intervention_name>
    <description>To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.</description>
    <arm_group_label>Asthma with NP and require surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent asthma and grade II and III bilateral sinonasal polyposisand, by
        voluntary decision of the otolaryngologist and the patient, who will offer alternatives
        treatment to the candidate patient, following the recommendations of clinical practice
        guidelines.

        If the patient is indicated in routine clinical practice FESS-BP, will be offer to enter to
        the study.

        If the patient is NOT indicated in routine clinical practice FESS-BP or reject
        intervention, will be also offer to enter to the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes aged ≥ 18 and younger than 70 years diagnosed with persistent
             asthma (according to GEMA4.0 criteria) (18) and grade II and III bilateral sinonasal
             polyposis of Lildholdlt (9,19), which, as indicated in routine clinical practice
             established by an otolaryngologist, will undergo FESS.

        Exclusion Criteria:

          -  Intermittent asthma;

          -  exacerbation of asthma that required treatment with parenteral steroids one month
             prior to visit 1;

          -  concomitance of other chronic respiratory diseases (bronchiectasis, fibrosis, etc.);

          -  other disabling severe comorbidities in the opinion of the investigators;

          -  previous noninflammatory sinonasal pathology;

          -  corticosteroid-dependent patients or managed with other immunomodulatory treatments.

          -  Patients with a history of previous nasal surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorena Soto-Retes, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorena Soto-Retes, physician</last_name>
    <phone>(+34) 935565972</phone>
    <email>lsoto@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lorena Soto-Retes</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gemasma.com</url>
    <description>Guía Española para el Manejo del Asma (GEMA) 4.0</description>
  </link>
  <results_reference>
    <citation>Johansson L, Akerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol. 2003 Jul;112(7):625-9.</citation>
    <PMID>12903683</PMID>
  </results_reference>
  <results_reference>
    <citation>Klossek JM, Neukirch F, Pribil C, Jankowski R, Serrano E, Chanal I, El Hasnaoui A. Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy. 2005 Feb;60(2):233-7.</citation>
    <PMID>15647046</PMID>
  </results_reference>
  <results_reference>
    <citation>Pérez De Llano LA, González FC, Añón OC, Perea MP, Caruncho MV, Villar AB; Proyecto Camaron (Control del Asma Mediante el Análisis Regular del Óxido Nítrico). [Relationship between comorbidity and asthma control]. Arch Bronconeumol. 2010 Oct;46(10):508-13. doi: 10.1016/j.arbres.2010.05.008. Epub 2010 Jul 17. Spanish.</citation>
    <PMID>20638762</PMID>
  </results_reference>
  <results_reference>
    <citation>Grossman J. One airway, one disease. Chest. 1997 Feb;111(2 Suppl):11S-16S. Review.</citation>
    <PMID>9042022</PMID>
  </results_reference>
  <results_reference>
    <citation>Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001 Mar;107(3):469-76.</citation>
    <PMID>11240947</PMID>
  </results_reference>
  <results_reference>
    <citation>Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003 Jun;111(6):1171-83; quiz 1184. Review.</citation>
    <PMID>12789212</PMID>
  </results_reference>
  <results_reference>
    <citation>Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160. doi: 10.1111/j.1398-9995.2007.01620.x. Review.</citation>
    <PMID>18331513</PMID>
  </results_reference>
  <results_reference>
    <citation>Alobid I, Antón E, Armengot M, Chao J, Colás C, del Cuvillo A, Dávila I, Dordal MT, Escobar C, Fernández-Parra B, Gras-Cabrerizo JR, Ibáñez MD, Lluch M, Matéu V, Montoro J, Gili JR, Mullol J, Navarro AM, Pumarola F, Rondón C, Sánchez-Hernández MC, Sarandeses A, Soler R, Valero AL; Rhinoconjunctivitis Committee; Spanish Society of Allergy and Clinical Immunology; Rhinology and Allergy Commission; Spanish Society of Otorhinolaryngology. SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project. J Investig Allergol Clin Immunol. 2011;21 Suppl 1:1-58.</citation>
    <PMID>21714471</PMID>
  </results_reference>
  <results_reference>
    <citation>Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012 Mar;50(1):1-12. doi: 10.4193/Rhino50E2.</citation>
    <PMID>22469599</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12. Erratum in: Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text.</citation>
    <PMID>24337046</PMID>
  </results_reference>
  <results_reference>
    <citation>Braunstahl GJ, Fokkens W. Nasal involvement in allergic asthma. Allergy. 2003 Dec;58(12):1235-43. Review.</citation>
    <PMID>14616096</PMID>
  </results_reference>
  <results_reference>
    <citation>Vashishta R, Soler ZM, Nguyen SA, Schlosser RJ. A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013 Oct;3(10):788-94. doi: 10.1002/alr.21182. Epub 2013 Jul 1. Review.</citation>
    <PMID>23818462</PMID>
  </results_reference>
  <results_reference>
    <citation>Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol Allied Sci. 1995 Feb;20(1):26-30.</citation>
    <PMID>7788929</PMID>
  </results_reference>
  <results_reference>
    <citation>American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30.</citation>
    <PMID>15817806</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>sinonasal polyposis</keyword>
  <keyword>eosinophilic bronchial inflammation</keyword>
  <keyword>endoscopic sinus surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

